RA Capital

“Parabilis priced at $20 (vs. a $17–$19 range), raised $670M, and carries a $2.34B market cap at listing, backed by Fidelity (11.3%), RA Capital (10%), and Arch Venture Partners (8.3%).”

“Hemab Therapeutics raised $301.5M in US IPO; backed by RA Capital and Novo Nordisk.”